John Somberg to Drug Industry
This is a "connection" page, showing publications John Somberg has written about Drug Industry.
Connection Strength
3.748
-
The conflict of interest charade. Am J Ther. 2013 Nov-Dec; 20(6):591.
Score: 0.473
-
The sins of ghostwriting. Am J Ther. 2008 Jul-Aug; 15(4):297-8.
Score: 0.327
-
Securing the US pharmaceutical supply. Am J Ther. 2008 May-Jun; 15(3):197.
Score: 0.323
-
Guilt by association. Am J Ther. 2007 May-Jun; 14(3):229-30.
Score: 0.302
-
The hypertension peril and drug development. Am J Ther. 2007 Jan-Feb; 14(1):2.
Score: 0.295
-
Off-label promotion. Am J Ther. 2006 Sep-Oct; 13(5):387.
Score: 0.288
-
Pharmaceutical companies and medical therapeutics education. Am J Ther. 2006 Mar-Apr; 13(2):93.
Score: 0.278
-
Genetic polymorphisms. Am J Ther. 2002 Jul-Aug; 9(4):271.
Score: 0.216
-
Old drugs, new bottles, therapeutic advantage? Am J Ther. 2002 Jul-Aug; 9(4):273-4.
Score: 0.216
-
Are we overregulated? Am J Ther. 2001 Jan-Feb; 8(1):1-2.
Score: 0.195
-
The cost of therapy. Am J Ther. 2000 Nov; 7(6):343-4.
Score: 0.192
-
Composite end points, black box warnings, and allegations of bias. Am J Ther. 2010 May-Jun; 17(3):233.
Score: 0.093
-
The cholesterol hypothesis: questioned? Am J Ther. 2008 May-Jun; 15(3):292-5.
Score: 0.081
-
FDA user fees and innovation. Am J Ther. 2008 Mar-Apr; 15(2):97.
Score: 0.080
-
Mandatory post marketing studies. Am J Ther. 2007 Jul-Aug; 14(4):321.
Score: 0.076
-
Physician specific prescribing information. Am J Ther. 2006 Nov-Dec; 13(6):465.
Score: 0.073
-
Lessons learned from the COX-2 advisory hearings. Am J Ther. 2005 Mar-Apr; 12(2):105.
Score: 0.065
-
The politics of therapeutics. Am J Ther. 2004 Nov-Dec; 11(6):422.
Score: 0.063
-
Should statins go OTC. Am J Ther. 2004 Jan-Feb; 11(1):1-2.
Score: 0.060
-
The generic conundrum. Am J Ther. 2002 Mar-Apr; 9(2):87-8.
Score: 0.053